An irradiation-free nonmyeloablative bone marrow transplantation model: Importance of the balance between donor T-cell number and the intensity of conditioning

Transplantation

Volumn 80, Issue 9, 2005, Pages 1145-1152

  Kuwatani, Masaki ^a,b   Ikarashi, Yoshinori ^a   Mineishi, Shin ^c   Asaka, Masahiro ^b   Wakasugi, Hiro ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Balance; Bone marrow transplantation; Nonmyeloablative; T cell

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CELL COUNT; CHIMERA; DONOR; FEMALE; IRRADIATION; MORTALITY; MOUSE; NONHUMAN; NONMYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE;

ANIMALS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CELL TRANSPLANTATION; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT VS HOST DISEASE; LYMPHOCYTE COUNT; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; SPLEEN; T-LYMPHOCYTES; TISSUE DONORS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 28544446843     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000183289.79693.3d     Document Type: Article

References (43)

1. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750-758.
2. Ueno NT, Rondon G, Mirza NQ, et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cacer. J Clin Oncol 1998; 16: 986-993.
3. Prigozhina TB, Gurevitch O, Slavin S. Nonmyeloablative conditioning to induce bilateral tolerance after allogeneic bone marrow transplantation in mice. Exp Hematol 1999; 27: 1503-1510.
4. Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood 2001; 98: 3456-3464.
5. Wulf GG, Luo KL, Goodell MA, Brenner MK. Anti-CD45-mediated cytoreduction to facilitate allogeneic stem cell transplantation. Blood 2003; 101: 2434-2439.
6. Kean LS, Durham MM, Adams AB, et al. A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation. Blood 2002; 99: 1840-1849.
7. Pan Y, Luo B, Sozen H, et al. Blockade of the CD40/CD154 pathway enhances T-cell-depleted allogeneic bone marrow engraftment under nonmyeloablative and irradiation-free conditioning therapy. Transplantation 2003; 76: 216-224.
8. Wu T, Sozen H, Luo B, et al. Rapamycin and T cell costimulatory blockade as post-transplant treatment promote fully MHC-mismatched allogeneic bone marrow engraftment under irradiation-free conditioning therapy. Bone Marrow Transplant 2002; 29: 949-956.
9. Xu H, Exner BG, Cramer DE, et al. CD8(+), alphabeta-TCR(+), and gammadelta-TCR(+) cells in the recipient hematopoietic environment mediate resistance to engraftment of allogeneic donor bone marrow. J Immunol 2002; 168: 1636-1643.
10. Suzue K, Reinherz EL, Koyasu S. Critical role of NK but not NKT cells in acute rejection of parental bone marrow cells in F1 hybrid mice. Eur J Immunol 2001; 31: 3147-3152.
11. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995; 13: 2431-2448.
12. Frank DA, Mahajan S, Ritz J. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med 1999; 5: 444-447.
13. Petrus MJ, Williams JF, Eckhaus MA, et al. An immunoablative regimen of fludarabine and cyclophosphamide prevents fully MHC-mismatched murine marrow graft rejection independent of GVHD. Biol Blood Marrow Transplant 2000; 6: 182-189.
14. Gregoire V, Van NT, Stephens LC, et al. The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine tumor radiation response in vivo. Cancer Res 1994; 54: 6201-6209.
15. Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001; 98: 3192-3204.
16. Chakrabarti S, McDonald D, Milligan DW. T cell-depleted nonmyeloablative stem cell transplantation: what is the optimum balance between the intensity of host conditioning and the degree of T cell depletion of the graft? Bone Marrow Transplant 2001; 28: 313-314.
17. Ceredig R, Lowenthal JW, Nabholz M, Macdonald HR. Expression of interleukin-2 receptors as a differentiation marker on intrathymic stem cells. Nature 1985; 314: 98-100.
18. Fuchs EJ, Matzinger P. B cells turn oft virgin but not memory T cells. Science 1992; 258: 1156-1159.
19. Julius MHE, Simpson E, Herzenberg L. A rapid method for the isolation of functional thymus-derived lymphocytes. Eur J Immunol 1973; 3: 645-649.
20. Cooke KR, Kobzik L, Martin TR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 1996; 88: 3230-3239.
21. Plunkett W, Saunders PP. Metabolism and action of purine nucleoside analogs. Pharmacol Ther 1991; 49: 239-268.
22. Guo Z, Wu T, Sozen H, et al. A substantial level of donor hematopoietic chimerism is required to protect donor-specific islet grafts in diabetic NOD mice. Transplantation 2003; 75: 909-915.
23. Tschetter JR, Mozes E, Shearer GM. Progression from acute to chronic disease in a murine parent-into-F1 model of graft-versus-host disease. J Immunol 2000; 165: 5987-5994.
24. Soderling CC, Song CW, Blazar BR, Vallera DA. A correlation between conditioning and engraftment in recipients of MHC-mismatched T cell-depleted murine bone marrow transplants. J Immunol 1985; 135: 941-946.
25. Panse JP, Bastianelli C, Santos EB, et al. Dog leukocyte antigen non-identical unrelated canine marrow grafts: enhancement of engraftment by CD4 and CD8 T cells. Transplantation 2003; 76: 474-480.
26. Jiang Z, Adams GB, Hanash AM, et al. The contribution of cytotoxic and noncytotoxic function by donor T-cells that support engraftment after allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2002; 8: 588-596.
27. Kreiter S, Winkelmann N, Schneider PM, et al. Failure of sustained engraftment after non-myeloablative conditioning with low-dose TBI and T cell-reduced allogeneic peripheral stem cell transplantation. Bone Marrow Transplant 2001; 28: 157-161.
28. Vallera DA, Blazar BR. T cell depletion for graft-versus-host-disease prophylaxis. A perspective on engraftment in mice and humans. Transplantation 1989; 47: 751-760.
29. Uharek L, Gassmann W, Glass B, et al. Influence of cell dose and graft-versus-host reactivity on rejection rates after allogeneic bone marrow transplantation. Blood 1992; 79: 1612-1621.
30. Gengozian N, Carlson DE, Allen EM. Transplantation of allogeneic and xenogeneic (rat) marrow in irradiated mice as affected by radiation exposure rates. Transplantation 1969; 7: 259-273.
31. Reisner Y, Martelli MF. Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells. Immunol Today 1995; 16: 437-440.
32. Ferrara J, Lipton J, Hellman S, et al. Engraftment following T-cell-depleted marrow transplantation. I. The role of major and minor histocompatibility barriers. Transplantation 1987; 43: 461-467.
33. Khouri I, Saliba R, Giralt S, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98: 3595-3599.
34. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
35. Ritchie DS, Morion J, Szer J, et al. Graft-versus-host disease, donor chimerism, and organ toxicity in stem cell transplantation after conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 2003; 9: 435-442.
36. Childs R, Clave E, Contentin N, et al. Engraftment kinetics after non-myeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999; 94: 3234-3241.
37. Mattson J, Uzunel M, Brune M, et al. Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol 2001; 115: 935-944.
38. Mapara MY, Kim Y-M, Wang S-P, et al. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cell. Blood 2002; 100: 1903-1909.
39. Mineishi S, Schuening FG. Graft-versus-host disease in mini-transplant. Leuk Lymphoma 2004; 45: 1969-1980.
40. Mineishi S, Kanda Y, Saito T, Nakai K, et al. Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies. Br J Haematol 2003; 121: 296-303.
41. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplant. Science 2002; 295: 2097-2100.
42. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve gratt-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003; 9: 1144-1150.
43. Zeng D, Lewis D, Dejbakhsh-Jones S, et al. Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease. J Exp Med 1999; 189: 1073-1081.